Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1462006

USP

Niacinamide

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Nicotinamide, Niacinamide, Nicotinic acid amide, Pyridine-3-carboxylic acid amide, Vitamin B3, Vitamin PP

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H6N2O
CAS Number:
98-92-0
Molecular Weight:
122.12
Beilstein:
383619
MDL number:
MFCD00006395
UNSPSC Code:
41116107
PubChem Substance ID:
329750553
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nicotinamide

manufacturer/tradename

USP

mp

128-131 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Niacinamide USP reference standard for use in specified quality tests and assays.

Also used to prepare standard, Niacin standard solution, standard niacinamide stock solution, and sample solution for assay, performance, and strength analysis according to the given below monographs and general chapters of United States Pharmacopeia (USP):
  • Niacinamide
  • Niacinamide Tablets
  • Niacinamide Injection
  • 〈441〉 Niacin or Niacinamide Assay

Biochem/physiol Actions

Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

N0600000

Nicotinamide, European Pharmacopoeia (EP) Reference Standard

E2400000

Ethylnicotinamide, European Pharmacopoeia (EP) Reference Standard

BP460

Nicotinamide, British Pharmacopoeia (BP) Reference Standard

BP1104

N-(2-Hydroxyethyl)isonicotinamide nitric ester, British Pharmacopoeia (BP) Reference Standard

PHR2089

Nicotinamide Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2090

Nicotinamide Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2088

Nicotinamide Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2087

Nicotinamide Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

302.0 °F - closed cup

Flash Point(C)

150 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Niacinamide Injection
United States Pharmacopeia, 46(5) (2023)
Mitchell E Horwitz et al.
The Journal of clinical investigation, 124(7), 3121-3128 (2014-06-10)
Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis
Geert O Janssens et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1112-1119 (2014-01-16)
Retrospective studies indicate that larger tumour volume is a strong prognostic indicator for poor tumour control after (chemo)radiotherapy for laryngeal cancer. The impact of tumour volume on the outcome of patients treated within a prospective study comparing accelerated radiotherapy (AR)±carbogen
Marcia S Brose et al.
Lancet (London, England), 384(9940), 319-328 (2014-04-29)
Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment
Fabrizio Montecucco et al.
Current drug targets, 14(6), 637-643 (2013-03-28)
Nicotinamide adenine dinucleotide (NAD+) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD+ stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service